Division of Hematology, Department of Internal Medicine, School of Medicine.
Department of Comprehensive Cancer Therapy, School of Medicine, and.
Blood Adv. 2018 Oct 23;2(20):2704-2712. doi: 10.1182/bloodadvances.2018022723.
Dysregulation of T-cell-mediated immunity is responsible for acquired pure red cell aplasia (PRCA). Although mutations are frequently detected in patients with T-cell large granular lymphocytic leukemia (T-LGLL), which is often complicated by PRCA and which is also reported to be associated with acquired aplastic anemia (AA) and myelodysplastic syndrome (MDS), whether -mutated T cells are involved in the pathophysiology of PRCA and other types of bone marrow failure remains unknown. We performed mutation analyses of the peripheral blood mononuclear cells from PRCA patients (n = 42), AA (n = 54), AA-paroxysmal nocturnal hemoglobinuria (AA-PNH; n = 7), and MDS (n = 21) using an allele-specific polymerase chain reaction and amplicon sequencing. mutations were not detected in any of the 82 patients with AA/PNH/MDS but were detected in 43% of the 42 PRCA patients. In all 7 -mutation-positive patients who were studied, the mutations were restricted to sorted CD8 T cells. The prevalence of mutation in idiopathic, thymoma-associated, autoimmune disorder-associated, and T-LGLL-associated PRCA was 33% (5 of 15), 29% (2 of 7), 20% (1 of 5), and 77% (10 of 13), respectively. The -mutation-positive patients were younger (median age, 63 vs 73 years; = .026) and less responsive to cyclosporine (46% [6 of 13] vs 100% [8 of 8]; = .0092) in comparison with -mutation-negative patients. The data suggest that -mutated CD8 T cells may be closely involved in the selective inhibition of erythroid progenitors in PRCA patients.
T 细胞介导的免疫失调是获得性纯红细胞再生障碍性贫血(PRCA)的原因。虽然 T 细胞大颗粒淋巴细胞白血病(T-LGLL)患者常伴有 PRCA,且该疾病也与获得性再生障碍性贫血(AA)和骨髓增生异常综合征(MDS)相关,并且据报道与 T-LGLL 相关,但其-突变 T 细胞是否参与 PRCA 和其他类型的骨髓衰竭的病理生理学尚不清楚。我们使用等位基因特异性聚合酶链反应和扩增子测序对 PRCA 患者(n=42)、AA(n=54)、AA-阵发性睡眠性血红蛋白尿症(AA-PNH;n=7)和 MDS(n=21)的外周血单个核细胞进行了-突变分析。在所有 82 例 AA/PNH/MDS 患者中均未检测到-突变,但在 42 例 PRCA 患者中有 43%检测到-突变。在所有 7 例-突变阳性患者中,-突变仅限于分选的 CD8 T 细胞。特发性、胸腺瘤相关、自身免疫性疾病相关和 T-LGLL 相关 PRCA 中的-突变发生率分别为 33%(15 例中的 5 例)、29%(7 例中的 2 例)、20%(5 例中的 1 例)和 77%(13 例中的 10 例)。与-突变阴性患者相比,-突变阳性患者年龄更小(中位数年龄,63 岁比 73 岁;=0.026),且对环孢素的反应更差(46%[13 例中的 6 例]比 100%[8 例中的 8 例];=0.0092)。数据表明,-突变的 CD8 T 细胞可能与 PRCA 患者中红系祖细胞的选择性抑制密切相关。